PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue (Form 8-K)

PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

Q4 2025 revenue growth of 14% year-over-year, driven by strong Revio and Vega shipments and record consumables revenue

MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) - PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6 million and $160.0 million representing year-over-year growth of 14% and 4%, respectively.

"We finished the year with strong momentum driven by increased Revio and Vega sales as well as record consumables revenue, reflecting meaningful traction across a range of clinical sequencing applications," said Christian Henry, President and CEO of PacBio. "In 2025, we also significantly reduced our cash burn and strengthened our financial profile. Looking ahead, we believe that increased real-world evidence in the clinic, combined with the significantly lower costs enabled by SPRQ-Nx, will catalyze our next phase of growth in 2026 and beyond."

Fourth quarter and full year results:

			Q4 2025 (Preliminary, unaudited)			Q4 2024			2025 (Preliminary, unaudited)			2024
Revenue (in millions)			~$44.6			$39.2			~$160.0			$154.0
Instrument revenue (in millions)			~$17.3			$15.3			~$53.8			$65.8
Consumable revenue (in millions)			~$21.6			$18.8			~$81.9			$70.3
Service and other revenue (in millions)			~$5.7			$5.1			~$24.3			$17.9
RevioTM system placements			21			23			61			97
VegaTM system placements			42			7			140			7
Annualized Revio pull-through per system			~$242,000			~$240,000
Ending cash, cash equivalents, and investments (in millions)			~$279.5			$389.9

PacBio is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 10:30 a.m. Pacific Time. PacBio plans to make the presentation available on the Events & Presentations Section of PacBio's website at investor.pacificbiosciences.com. The information posted on or that can be accessed through PacBio's website, including PacBio's updated corporate presentation, is not incorporated by reference into this press release, and the inclusion of PacBio's website address is an inactive textual reference only.

The preliminary unaudited financial information set forth above is subject to revision and is anticipated to be finalized when the Company files its 2025 Annual Report on Form 10-K. PacBio's final, audited financial results could differ materially from the preliminary estimates above, which are not a comprehensive statement of PacBio's financial results and are not necessarily indicative of the results to be expected as of or for the fiscal period ended December 31, 2025, or any future period. Accordingly, you should not place undue reliance on these preliminary estimates. PacBio preliminarily expects to report its fourth quarter 2025 results during a conference call in February, at which point it will discuss its 2025 financial results in more detail.

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.